The US market for Hemostats and Sealants regained its pre-pandemic stride in Q321 as many procedures mostly returned to normal volumes.

Hashed Health CEO John Bass discusses how Hashed Health is bringing blockchain technology to healthcare in an interview with SmartTRAK

In an interview with SmartTRAK, Hashed Health CEO John Bass discusses the Company and the use case of blockchain and distributed ledger technology in the medical device industry. Hashed Health is a venture product studio that partners with healthcare and life science enterprises to introduce new blockchain-based healthcare solutions to market.

To find out more, including why blockchain technology is important for medical device manufacturers, click on the following video to listen to the full interview (25:42 min). A link to download the complete transcript of the interview is also provided below.

Covid-related challenges continued to dampen market recovery in Q321. Despite pandemic hurdles, technology that improves surgical precision and real-time workflows is driving adoption and innovation in computer-assisted spine surgery and accelerating the development of products and systems.

Many companies with established enabling technologies are pushing to expand indications for existing systems and bolster them with robust preoperative planning, enhanced navigation and post-op evaluation solutions for start-finish integration within a single line of products. Meanwhile, other players are focusing on open-platform solutions to address care gaps for specific procedures and populations. At the forefront of industry research and development are artificial intelligence and virtual reality technologies to aid in imaging, planning and navigation assistance (robotic-assisted and freehand). 

Renewed COVID-19 headwinds mute overall Q3 results, however, the soft tissue repair segment remains resilient

Impact of the Delta variant was felt broadly across OrthoBio, with virtually all publicly traded companies observing a reduction in surgical volume (relative to forecast) directly attributable to a resurgence of COVID-19. Overall, OrthoBio revenue declined, primarily driven by a sharp reduction in Bone Replacement revenue. Several companies noted the decrease in surgical volumes was most acute in August and September due to shortages in hospital staffing. Weakness was most closely tied to deferrable, elective, complex spine procedures.

Among the many topics covered in detail in our comprehensive Q321 OrthoBio Market Recap* are:

Trauma market continues to ride the wave of healthy growth with positive returns for current players and new players start to stir the waters

Trauma players rode the wave of another quarter of healthy returns as trauma procedures were not as impacted by the rise in the Delta variant as its elective procedure counterparts. The Trauma Market closed Q3 up +4.5% YoY compared to Q320, with the US up +5.8% YoY.

Among the many topics covered in detail in our comprehensive Q321 Trauma Market Recap* are:

Advanced Wound Care (AWC) continues to rebound in 2021 with growth from US Skin Substitutes and WW Advanced Dressings despite weakness in NPWT.

The WW Advanced Wound Care (AWC) market grew +6.5% YoY in Q321, according to the SmartTRAK Financial Dashboard.

The WW AWC market is made up of a diverse array of wound care products comprising the segments of Advanced Dressings, Wound Biologics and External Devices. WW Advanced Dressings grew in Q3, driven by robust gains in Foams, Antimicrobials and Superabsorbents. WW Wound Biologics showed continued gains among US Skin Substitute market leaders. WW External Devices (of which NPWT makes up 96%) was mostly flat due to delta variant headwinds and low elective procedure volumes slowing growth.

Among the many topics covered in detail in our comprehensive Q321 Advanced Wound Care Market Recap* are:

OsteoCentric Technologies' CMO Gavin Sontag discusses the Company and its OssiMI mechanical integration technology in an interview with SmartTRAK.

Gavin Sontag, CMO of OsteoCentric Technologies, discusses OsteoCentric's OssiMI platform technology, company growth rates and plans for expansion in an interview with SmartTRAK. To find out more, including why OsteoCentric acquired an SI-Fusion system, click on the following video. A link to download the complete transcript of the interview is also provided below.

Q321 results were a letdown compared to the previous quarter as COVID-19 continues to burst HA players’ bubble but hopes for a return to normal prevail.

Spring 2021 brought on much relief to the US Joint Fluid Replacement market and the summer looked promising for a return to normal business conditions. However, as more cases of COVID-19 Delta variant were reported, especially in key hyaluronic acid (HA) states, like Texas and Florida, companies were left as though their bubble got burst. Some players expressed concerns that volumes could be depressed for Q421 since it does not seem to be picking up as fast as they projected. But, for Q321 and for the most part, the majority of HA market players did report positive revenue increases in the third quarter.

Among the many topics covered in detail in our comprehensive Q321 US Joint Fluid Replacement Market Recap* are:

As a tumultuous year comes to a finish, the orthopedic industry prepares to gather one last time and close out the year. The Orthopedic Summit once again comes to the Bellagio in Las Vegas, Nevada to bring together the top names in the industry. SmartTRAK will be attending OSET 2021 from December the 11th through the 14th. We've put together an overview of recent Orthopedic news highlights to get you up to speed before the meeting. If you'd like to meet with us in person, please reach out.

The following is just a small sampling of recent Orthopedics related news and updates from around the world compiled, reviewed and posted in real time every day by the expert analysts at SmartTRAK.

Markets:

• Needham Ortho Surgeon Expert Call Highlights
  During a call co-hosted by Needham, Hip and Knee surgeon Dr. Richard Berkowitz of Tamrac, FL, noted COVID accelerated the shift of recon procedures to the outpt setting w/ ~10-20% of his procedures outpt to increase to ~40-50% over the next few yrs. Needham Ortho Expert Call
  
  
• Knee Market Leaders See Share Gains in Q321
  According to SmartTRAK Financial Dashboard, US knee replacement implant market leader Zimmer Biomet* saw improved market share sequentially in Q321 compared to Q221. Stryker* also experienced an increase in share compared to Q221.
  
  
• OTA 2021 Updates
  

  DePuy Synthes* showcased their long awaited 3.5/4.5 VA-LCP Periprosthetic Femur Plate*. According to SmartTRAK discussions, the periprosthetic plate spans the femur and is currently in limited launch w/ ~50 sets in the field and full set rollout to commence next year.

Procedures using surgical matrices maintained their new normal, with broad strength in both hernia and breast matrices.

Procedures using surgical matrices maintained their new normal, though the resurgence of Delta variant across the northern tier of states may put a dent in the market following deferrals of procedures in various regions as the COVID-19 Delta variant caused more procedural headwinds.

Among the many topics covered in detail in our comprehensive Q321 US Surgical Matrices Market Recap* are: